These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 15997131)

  • 1. Preparation of highly potent and selective non-peptide antagonists of the arginine vasopressin V1A receptor by introduction of a 2-ethyl-1H-1-imidazolyl group.
    Shimada Y; Akane H; Taniguchi N; Matsuhisa A; Kawano N; Kikuchi K; Yatsu T; Tahara A; Tomura Y; Kusayama T; Wada K; Tsukada J; Tsunoda T; Tanaka A
    Chem Pharm Bull (Tokyo); 2005 Jul; 53(7):764-9. PubMed ID: 15997131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation of non-peptide, highly potent and selective antagonists of arginine vasopressin V1A receptor by introduction of alkoxy groups.
    Shimada Y; Taniguchi N; Matsuhisa A; Yatsu T; Tahara A; Tanaka A
    Chem Pharm Bull (Tokyo); 2003 Sep; 51(9):1075-80. PubMed ID: 12951451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 2-phenyl-4'-(2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-1-carbonyl) benzanilide derivatives.
    Matsuhisa A; Koshio H; Sakamoto K; Taniguchi N; Yatsu T; Tanaka A
    Chem Pharm Bull (Tokyo); 1998 Oct; 46(10):1566-79. PubMed ID: 9810694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 4'-[5-(substituted methylidene)-2,3,4,5-tetrahydro-1H-1-ben zoazepine-1-carbonyl]benzanilide and 4'-[5-(substituted methyl)-2,3-dihydro-1H-1-benzoazepine-1- carbonyl]benzanilide derivatives.
    Matsuhisa A; Kikuchi K; Sakamoto K; Yatsu T; Tanaka A
    Chem Pharm Bull (Tokyo); 1999 Mar; 47(3):329-39. PubMed ID: 10212383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 2-phenyl-4'-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]benzanil ide derivatives.
    Matsuhisa A; Tanaka A; Kikuchi K; Shimada Y; Yatsu T; Yanagisawa I
    Chem Pharm Bull (Tokyo); 1997 Nov; 45(11):1870-4. PubMed ID: 9396163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Highly potent and orally active non-peptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 4'-[(4,4-difluoro-5-methylidene-2,3,4,5-tetrahydro-1H-1-benzoazepin-1-y l)carbonyl]-2-phenylbenzanilide derivatives.
    Shimada Y; Taniguchi N; Matsuhisa A; Sakamoto K; Yatsu T; Tanaka A
    Chem Pharm Bull (Tokyo); 2000 Nov; 48(11):1644-51. PubMed ID: 11086891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological activity of novel 4,4-difluorobenzazepine derivatives as non-peptide antagonists of the arginine vasopressin V1A receptor.
    Shimada Y; Taniguchi N; Matsuhisa A; Akane H; Kawano N; Suzuki T; Tobe T; Kakefuda A; Yatsu T; Tahara A; Tomura Y; Kusayama T; Wada K; Tsukada J; Orita M; Tsunoda T; Tanaka A
    Bioorg Med Chem; 2006 Mar; 14(6):1827-37. PubMed ID: 16290163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 4-(1,4,5,6-tetrahydroimidazo[4,5-d][1]benzoazepine-6-carbonyl)benzanili de derivatives and 4'-(5,6-dihydro-4H-thiazolo[5,4-d][1]benzoazepine-6-carbonyl)benzanilid e derivatives.
    Matsuhisa A; Taniguchi N; Koshio H; Yatsu T; Tanaka A
    Chem Pharm Bull (Tokyo); 2000 Jan; 48(1):21-31. PubMed ID: 10705470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of YM218, a nonpeptide vasopressin V1A receptor-selective antagonist, on human vasopressin and oxytocin receptors.
    Tahara A; Tsukada J; Tomura Y; Kusayama T; Wada K; Ishii N; Taniguchi N; Suzuki T; Yatsu T; Uchida W; Shibasaki M
    Pharmacol Res; 2005 Mar; 51(3):275-81. PubMed ID: 15661579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Properties of a new radioiodinated antagonist for human vasopressin V2 and V1a receptors.
    Ala Y; Morin D; Mahé E; Cotte N; Mouillac B; Jard S; Barberis C; Tribollet E; Dreifuss JJ; Sawyer WH; Wo NC; Chan WY; Kolodziejczyk AS; Cheng LL; Manning M
    Eur J Pharmacol; 1997 Jul; 331(2-3):285-93. PubMed ID: 9274991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoyl-amino)benzoyl ]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): a potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist.
    Kondo K; Ogawa H; Yamashita H; Miyamoto H; Tanaka M; Nakaya K; Kitano K; Yamamura Y; Nakamura S; Onogawa T; Mori T; Tominaga M
    Bioorg Med Chem; 1999 Aug; 7(8):1743-54. PubMed ID: 10482466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conserved aromatic residues in the transmembrane region VI of the V1a vasopressin receptor differentiate agonist vs. antagonist ligand binding.
    Cotte N; Balestre MN; Aumelas A; Mahé E; Phalipou S; Morin D; Hibert M; Manning M; Durroux T; Barberis C; Mouillac B
    Eur J Biochem; 2000 Jul; 267(13):4253-63. PubMed ID: 10866830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vasopressin V1a and V1b receptor modulators: a patent review (2012 - 2014).
    Ślusarz MJ
    Expert Opin Ther Pat; 2015 Jun; 25(6):711-22. PubMed ID: 25776143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin.
    Manning M; Cheng LL; Stoev S; Bankowski K; Przybyiski J; Klis WA; Sawyer WH; Wo NC; Chan WY
    J Pept Sci; 1995; 1(1):66-79. PubMed ID: 9222985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of a new, potent, non-peptide V1a vasopressin antagonist, SR 49059, on the binding and the mitogenic activity of vasopressin on Swiss 3T3 cells.
    Serradeil-Le Gal C; Bourrié B; Raufaste D; Carayon P; Garcia C; Maffrand JP; Le Fur G; Casellas P
    Biochem Pharmacol; 1994 Feb; 47(4):633-41. PubMed ID: 8129742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vasopressin stimulates insulin release from islet cells through V1b receptors: a combined pharmacological/knockout approach.
    Oshikawa S; Tanoue A; Koshimizu TA; Kitagawa Y; Tsujimoto G
    Mol Pharmacol; 2004 Mar; 65(3):623-9. PubMed ID: 14978240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetamide derivatives as novel arginine vasopressin V(2) receptor agonists.
    Tsukamoto I; Koshio H; Akamatsu S; Kuramochi T; Saitoh C; Yatsu T; Yanai-Inamura H; Kitada C; Yamamoto E; Sakamoto S; Tsukamoto S
    Bioorg Med Chem; 2008 Nov; 16(21):9524-35. PubMed ID: 18835174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist.
    Serradeil-Le Gal C; Wagnon J; Simiand J; Griebel G; Lacour C; Guillon G; Barberis C; Brossard G; Soubrié P; Nisato D; Pascal M; Pruss R; Scatton B; Maffrand JP; Le Fur G
    J Pharmacol Exp Ther; 2002 Mar; 300(3):1122-30. PubMed ID: 11861823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spinal vasopressin alleviates formalin-induced nociception by enhancing GABAA receptor function in mice.
    Peng F; Qu ZW; Qiu CY; Liao M; Hu WP
    Neurosci Lett; 2015 Apr; 593():61-5. PubMed ID: 25782631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, tolerability, and pharmacokinetics of SR 49059, a V1a vasopressin receptor antagonist, after repeated oral administration in healthy volunteers.
    Brouard R; Laporte V; Serradeil Le Gal C; Pignol R; Jang H; Donat F; Lockwood G; Fournie D; Dreux F
    Adv Exp Med Biol; 1998; 449():455-65. PubMed ID: 10026839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.